DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for diffuse large B-cell lymphoma — screening already-approved drugs against its 42-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDiffuse large B-cell lymphoma maps to a 42-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedVincristineApproved drug
Structures already discussed alongside diffuse large b-cell lymphoma in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
bovine ABCC1 — Vincristine has a real, experimentally solved structure in complex with this target (PDB 9LGC, 2.95 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet r1qdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9LGC · 2.95 Å · ligand Vincristine (R1Q). Experimental structure, not a prediction.
What the evidence adds up to
Diffuse large B-cell lymphoma is the most common type of malignant lymphoma and an aggressive subtype of non-Hodgkin lymphoma. Gene expression profiling has identified three molecular subtypes: germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma (PMBL). The fourth edition of the World Health Organization consensus classification, revised in 2016, established refined diagnostic criteria based on these molecular identities and novel pathogenetic pathways identified through high-throughput technologies.
A 2024 RNA sequencing study compared DLBCL patients to controls using a fold-change threshold of ≥2 or ≤-2. It found 73 differentially expressed genes, of which 70 were downregulated and three were upregulated. Reactome pathway analysis linked these changes to downregulation of antimicrobial humoral response, neutrophil degranulation, chemokine receptors binding chemokines, defensins, and metabolism of angiotensinogen. The authors concluded these pathways may contribute to cancer progression and weaken immune response in DLBCL patients.
The 2024 study offers no survival data, response rates, or sample size. It does not test any drug or intervention. The earlier reviews describe molecular subtypes and classification updates but report no clinical trial results. No treatment is evaluated in any of the three abstracts.
What remains missing is any clinical trial testing a drug based on these gene expression or pathway findings, funding for such trials, and patient stratification by the molecular subtypes described. The 2024 study identifies potential downstream targets but provides no evidence that modulating them changes disease outcome.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Therapeutic Advances in Hematology · 2011 · 29 citations
The molecular biology of diffuse large B-cell lymphoma
AbstractDiffuse large B-cell lymphoma (DLBCL) represents the most common type of malignant lymphoma. In the last few years, significant progress has been achieved in the understanding of the molecular pathogenesis of this entity. Gene expression profiling has identified three molecular DLBCL subtypes, termed germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma (PMBL). In this review, we summarize our current understanding of the biology of these DLBCL subtypes with a special emphasis on novel diagnostic and therapeutic approaches.
Molecular Update and Evolving Classification of Large B-Cell Lymphoma
AbstractDiffuse large B-cell lymphomas (DLBCLs) are aggressive B-cell neoplasms with considerable clinical, biologic, and pathologic diversity. The application of high throughput technologies to the study of lymphomas has yielded abundant molecular data leading to the identification of distinct molecular identities and novel pathogenetic pathways. In light of this new information, newly refined diagnostic criteria have been established in the fourth edition of the World Health Organization (WHO) consensus classification of lymphomas, which was revised in 2016. This article reviews the histopathological and molecular features of the various aggressive B-cell lymphoma subtypes included in the updated classification.
Exploring Differentially Expressed Genes and Immune Modulation in Diffuse Large B-Cell Lymphoma through RNA Sequencing Analysis.
AbstractBackground: Diffuse large B-cell lymphoma (DLBCL) is globally recognized as the most prevalent and aggressive subtype of non-Hodgkin lymphoma. While conventional treatments are effective initially, the disease can become resistant or relapse over time. This study aimed to examine the differentially expressed genes at the transcriptome level and molecular pathways in DLBCL patients. Methods: fold change (FC) of ≥2 or ≤-2. Results: Results showed 73 differentially expressed genes between the two groups, among which 70 genes were downregulated, and three genes were upregulated. The differentially expressed genes analyzed with the Reactome pathway were significantly associated with the downregulation of antimicrobial humoral response (P<0.001), neutrophil degranulation (P<0.001), chemokine receptors bind chemokines (P=0.028), defensins (P=0.028) and metabolism of angiotensinogen (P=0.040). Conclusion: These findings suggest that the identified pathways may contribute to cancer progression and weaken the immune response in diffuse large B-cell lymphoma patients. This study offers fresh insights into previously undiscovered downstream targets and pathways modulated by diffuse large B-cell lymphoma.
SKIN The Journal of Cutaneous Medicine · 2021 · 0 citations · open access
Diffuse Large B-cell Lymphoma in Bilateral Lower Extremities
AbstractDiffuse large B-cell lymphoma, leg type, is a rare variant of primary cutaneous B-cell lymphomas. It typically presents as rapidly enlarging solitary or multiple violaceous nodules on the lower extremities. Even with adequate treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, recurrence and systemic spread is common. Timely treatment is necessary as this malignancy is associated with a more aggressive course than other variants of primary cutaneous B-cell lymphomas and overall prognosis is poor.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
